Alnylam Pharmaceuticals Inc
ALNY307.990USD
+3.320+1.09%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
40.13BMarket Cap
LossP/E TTM
More Details of Alnylam Pharmaceuticals Inc Company
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Company Info
Ticker SymbolALNY
Company nameAlnylam Pharmaceuticals Inc
IPO dateMay 28, 2004
Founded at2003
CEODr. Yvonne L. Greenstreet, M.D.
Number of employees2230
Security typeOrdinary Share
Fiscal year-endMay 28
Address675 W Kendall St
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142-1168
Phone16175518200
Websitehttps://www.alnylam.com/
Ticker SymbolALNY
IPO dateMay 28, 2004
Founded at2003
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.35K
--
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
+3.87%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
+21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.35K
--
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
+3.87%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
+21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
By RegionUSD
Name
Revenue
Proportion
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
12.85%
Fidelity Management & Research Company LLC
11.22%
The Vanguard Group, Inc.
9.97%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
55.32%
Shareholders
Shareholders
Proportion
Capital World Investors
12.85%
Fidelity Management & Research Company LLC
11.22%
The Vanguard Group, Inc.
9.97%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
55.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.08%
Investment Advisor/Hedge Fund
30.90%
Corporation
3.44%
Hedge Fund
3.14%
Sovereign Wealth Fund
2.00%
Research Firm
1.57%
Pension Fund
1.25%
Bank and Trust
1.12%
Individual Investor
0.39%
Institutional Shareholding
Updated: Sun, Jan 19
Updated: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1268
131.09M
100.54%
-4.40M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
T. Rowe Price Associates, Inc.
3.23M
2.48%
-123.23K
-3.68%
Dec 31, 2024
State Street Global Advisors (US)
3.42M
2.63%
-45.44K
-1.31%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Tema Neuroscience and Mental Health ETF
5.15%
VanEck Biotech ETF
5.11%
Global X Genomics & Biotechnology ETF
4.67%
Invesco Nasdaq Biotechnology ETF
4.1%
First Trust NYSE Arca Biotechnology Index Fund
3.92%
ProShares Ultra Nasdaq Biotechnology
3.9%
iShares Biotechnology ETF
3.6%
American Century Focused Dynamic Growth ETF
3.44%
Franklin Genomic Advancements ETF
3.19%
SPDR S&P Biotech ETF
3.05%
View more
Tema Neuroscience and Mental Health ETF
Proportion5.15%
VanEck Biotech ETF
Proportion5.11%
Global X Genomics & Biotechnology ETF
Proportion4.67%
Invesco Nasdaq Biotechnology ETF
Proportion4.1%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.92%
ProShares Ultra Nasdaq Biotechnology
Proportion3.9%
iShares Biotechnology ETF
Proportion3.6%
American Century Focused Dynamic Growth ETF
Proportion3.44%
Franklin Genomic Advancements ETF
Proportion3.19%
SPDR S&P Biotech ETF
Proportion3.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
